Dupilumab De-escalation in Pediatric Atopic Dermatitis: A Pilot Trial

Conditions: Atopic Dermatitis Interventions: Drug: Dupilumab - Discontinuation; Drug: Dupilumab - Dose Reduction; Drug: Dupilumab - Standard Dose Sponsors: Johns Hopkins University; Doris Duke Charitable Foundation Not yet recruiting

https://clinicaltrials.gov/study/NCT06116526

Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials

More News: Dermatitis | Dermatology | John Hopkins University | Pediatrics | Research